Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110 as a Potential Anticancer Agent

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02115, USA.
Cancer Discovery (Impact Factor: 19.45). 05/2012; 2(5):425-33. DOI: 10.1158/2159-8290.CD-12-0003
Source: PubMed


Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collection of compounds possessing activities against kinases in the PI3K superfamily and identified a potent and selective p110β inhibitor: KIN-193. We show that KIN-193 is efficacious specifically in blocking AKT signaling and tumor growth that are dependent on p110β activation or PTEN loss. Broad profiling across a panel of 422 human tumor cell lines shows that the PTEN mutation status of cancer cells strongly correlates with their response to KIN-193. Together, our data provide the first pharmacologic evidence that PTEN-deficient tumors are dependent on p110β in animals and suggest that KIN-193 can be pursued as a drug to treat tumors that are dependent on p110β while sparing other PI3K isoforms. SIGNIFICANCE: We report the first functional characterization of a p110β-selective inhibitor, KIN-193, that is efficacious as an antitumor agent in mice. We show that this class of inhibitor holds great promise as a pharmacologic agent that could be used to address the potential therapeutic benefit of treating p110β-dependent PTEN-deficient human tumors.

Download full-text


Available from: Nathanael Gray,
    • "Although no therapies have been approved for patients with Cowden syndrome, clinical trials are evaluating the role of PIK3CA/mTOR inhibitors such as sirolimus (NCI trial #NCT00971789), BGT226 (NCI trial #NCT00600275), and BEZ235 (NCI trial #NCT00620594) for the treatment of malignancies in these patients. It is also noteworthy that preclinical models have suggested that PTEN deficient tumors depend on p110 beta isoforms of PI3K, and inhibition of p110 beta is sufficient to inhibit tumor formation driven by PTEN loss (Ni et al., 2012). Selective PI3K beta inhibitors may have better activity and tolerability in patients with Cowden syndrome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome are cancer syndromes which affect multiple organs and lead to significant decline in quality of life in affected patients. These syndromes are rare and typically affect the adolescent and young adult population, resulting in greater cumulative years of life lost. Improved understanding of the underpinnings of the genetic pathways underlying these syndromes and the rapid evolution of targeted therapies in general have made it possible to develop therapeutic options for these patients and other genetic cancer syndromes. Targeted therapies especially antiangiogenics and inhibitors of the PIK3CA/AKT/mTOR signaling pathway have shown activity in selected group of patients affected by these syndromes or in patients harboring specific sporadic mutations which are otherwise characteristic of these syndromes. Unfortunately due to the rare nature, patients with these syndromes are not the focus of clinical trials and unique results seen in these patients can easily go unnoticed. Most of the data suggesting benefits of targeted therapies are either case reports or small case series. Thus, a literature review was indicated. In this review we explore the use of molecularly targeted therapy options in Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.
    Discovery medicine 02/2015; 19(103):109-116. · 3.63 Impact Factor
  • Source
    • "At least theoretically, distinct PI3K Class I requirements could influence the efficiency of preconditioning treatments in subsets of patients at risk for myocardial infarction and presenting with medication and co-morbidities that differentially affect Class IA and IB PI3K [28] [29] [30]. Likewise, selective PI3K isoform inhibitors used in the treatment of inflammatory diseases and cancer [31] [32] [33] may affect the efficacy of preconditioning treatments in the heart of these patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute myocardial infarction, the clinical manifestation of ischemia-reperfusion (IR) injury, is a leading cause of death worldwide. Like ischemic preconditioning (IPC) induced by brief episodes of ischemia and reperfusion, ouabain preconditioning (OPC) mediated by Na/K-ATPase signaling protects the heart against IR injury. Class I PI3K activation is required for IPC, but its role in OPC has not been investigated. While PI3K-IB is critical to IPC, studies have suggested that ouabain signaling is PI3K-IA-specific. Hence, a pharmacological approach was used to test the hypothesis that OPC and IPC rely on distinct PI3K-I isoforms. In Langendorff-perfused mouse hearts, OPC was initiated by 4min of ouabain 10μM and IPC was triggered by 4cycles of 5min ischemia and reperfusion prior to 40min of global ischemia and 30min of reperfusion. Without affecting PI3K-IB, ouabain doubled PI3K-IA activity and Akt phosphorylation at Ser(473). IPC and OPC significantly preserved cardiac contractile function and tissue viability as evidenced by left ventricular developed pressure and end-diastolic pressure recovery, reduced lactate dehydrogenase release, and decreased infarct size. OPC protection was blunted by the PI3K-IA inhibitor PI-103, but not by the PI3K-IB inhibitor AS-604850. In contrast, IPC-mediated protection was not affected by PI-103 but was blocked by AS-604850, suggesting that PI3K-IA activation is required for OPC while PI3K-IB activation is needed for IPC. Mechanistically, PI3K-IA activity is required for ouabain-induced Akt activation but not PKCε translocation. However, in contrast to PKCε translocation which is critical to protection, Akt activity was not required for OPC. Further studies shall reveal the identity of the downstream targets of this new PI3K IA-dependent branch of OPC. These findings may be of clinical relevance in patients at risk for myocardial infarction with underlying diseases and/or medication that could differentially affect the integrity of cardiac PI3K-IA and IB pathways. Copyright © 2014. Published by Elsevier Ltd.
    Journal of Molecular and Cellular Cardiology 01/2015; 80. DOI:10.1016/j.yjmcc.2014.12.021 · 4.66 Impact Factor
  • Source
    • "We speculate that this p110b-depend- ent rebound of PIP 3 requires several hours to manifest for two main reasons: (1) the time required for maximal BYL719-depen- dent release of the negative feedbacks leading to tyrosine phosphorylation of PI3K activators (e.g., ERBB3) and subsequent p110b recruitment, and (2) since p110b is a relatively inefficient enzyme in comparison to p110a (Beeton et al., 2000), PIP 3 accumulation can only be observed after sufficient time following activation. Although p110b has been identified as the primary PI3K isoform driving PI3K signaling in PTEN null tumors (Jia et al., 2008; Ni et al., 2012), the experiments in this study suggest that p110b activation also promotes the viability of p110a-driven breast cancers following treatment with p110a-s- pecific inhibitors. In vivo, p110a inhibition blocked tumor growth but did not induce tumor shrinkage in either the HER2-amplified or PIK3CA mutant xenograft models. "
    [Show abstract] [Hide abstract]
    ABSTRACT: BYL719, which selectively inhibits the alpha isoform of the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (p110a), is currently in clinical trials for the treatment of solid tumors, especially luminal breast cancers with PIK3CA mutations and/or HER2 amplification. This study reveals that, even among these sensitive cancers, the initial efficacy of p110α inhibition is mitigated by rapid re-accumulation of the PI3K product PIP3 produced by the p110β isoform. Importantly, the reactivation of PI3K mediated by p110β does not invariably restore AKT phosphorylation, demonstrating the limitations of using phospho-AKT as a surrogate to measure PI3K activation. Consistently, we show that the addition of the p110β inhibitor to BYL719 prevents the PIP3 rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant cancers. Copyright © 2015 Elsevier Inc. All rights reserved.
    Cancer Cell 12/2014; 27(1). DOI:10.1016/j.ccell.2014.11.007 · 23.52 Impact Factor
Show more